J&J Stock Rises After Healthcare Giant Raises Outlook

Johnson & Johnson raised its adjusted earnings outlook for the year after posting higher third-quarter revenue, despite a drop in sales of its Covid-19 vaccine.

J&J’s shares, down nearly 11% this year, rose around 2% to $160.55 in premarket trading.